The Oncologist · 2004 · 55 citations · 18 references
MedicineOncologyPharmacologyChemotherapyClinical PharmacologyOncology PharmacotherapyAnemiaChemotherapy In Hematologic MalignanciesCommunity-based PracticeConcurrent TherapyHemoglobin Levels
PRIMARY PURPOSE: The objective of this retrospective observational cohort study was to compare the effectiveness of darbepoetin alfa with that of epoetin alfa in patients with chemotherapy-induced anemia using data from noncontemporaneous chart audits conducted at a community-based oncology practice. MATERIALS AND METHODS: For the first chart audit, data were collected from consecutive patients with nonmyeloid malignancies with diagnoses of chemotherapy-induced anemia and hemoglobin levels < or = 10.5 g/dl who were receiving concurrent chemotherapy and had at least 5 weeks of visits from July-September 2000. After therapeutic substitution of darbepoetin alfa for epoetin alfa for all patients with chemotherapy-induced anemia, data were collected from consecutive darbepoetin alfa-treated patients with diagnoses of chemotherapy-induced anemia and at least 8 weeks of visits from June-October 2002 (darbepoetin alfa was approved in July 2002). RESULTS: Most (86%) of the 212 epoetin alfa-treated patients had received an initial dose of 40,000 U once weekly, and most (85%) of the 196 darbepoetin alfa-treated patients had received a fixed dose of either 100 microg once weekly (49%) or 200 microg every 2 weeks (36%). At 8 weeks, the mean change in hemoglobin level was 1.1 g/dl for the darbepoetin alfa patient group and 1.0 g/dl for the epoetin alfa patient group. DISCUSSION: Utilization, dose escalation rates, and clinical outcomes were considered comparable for the darbepoetin alfa and epoetin alfa patient groups. CONCLUSIONS: Darbepoetin alfa, 100 microg once weekly or 200 microg every 2 weeks, appears to be as effective as epoetin alfa, 40,000 U once weekly, for the treatment of chemotherapy-induced anemia in the clinical practice setting.
18
Timothy J. Littlewood, Emilio Bajetta, J.W.R. Nortier et al. · Journal of Clinical Oncology · 2001 · 977 citations
Medicine, Hematology, Pharmacology +13
George D. Demetri, Mark G. Kris, James L. Wade et al. · Journal of Clinical Oncology · 1998 · 756 citations
Medicine, Oncology, Pharmacology +12
John A. Glaspy, Ronald Bukowski, Douglas Steinberg et al. · Journal of Clinical Oncology · 1997 · 705 citations
Medicine, Hematology, Pharmacology +13
Janice Gabrilove, Charles S. Cleeland, Robert B. Livingston et al. · Journal of Clinical Oncology · 2001 · 596 citations
Medicine, Hematology, Pharmacology +14
Enhancement of therapeutic protein in vivo activities through glycoengineering
Steve Elliott, Tony Lorenzini, Sheilah Asher et al. · Nature Biotechnology · 2003 · 516 citations